Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers

1. Quintela-Fandino, M.
2. Manso Sànchez, L.M.
3. Holgado Martín, E.
4. Moreno, M.C.
5. Morales Murillo, S.
6. Bermejo De Las Heras, B.
7. Malon Gimenez, D.
8. Colomer Bosch, R.
9. Gonzalez Cortijo, L.
10. Hornedo, J.
11. Mouron, S.
12. Muñoz, M.
13. Escudero, S.
14. Blanco, R.
15. Mañes, S.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1093/ANNONC/MDY430.003 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus